ABSTRACT
Numerous decellularized ECM medical products are currently on the market, including human dermis for abdominal wall and breast reconstruction and porcine small intestinal submucosa (SIS) for general soft tissue repair and reinforcement (Keane et al. 2012). While most products on the market utilize intact decellularized tissues, it is possible to produce an injectable form of decellularized ECM that gels within the patient. The use of these injectable ECM gels as bioactive scaffold for tissue engineering is currently under investigation for treatment of myocardial infarction, traumatic injury, and urinary incontinence (Young et al. 2011; Singelyn et al. 2012; Freytes et al. 2008).
